Eight of 16 patients participating in a study of an experimental immune system therapy directed against the most aggressive malignant brain tumors - glioblastoma multiforme - survived longer than five years after diagnosis, according to Cedars-Sinai researchers, who presented findings Nov. 23 at the Fourth Quadrennial Meeting of the World ... (more)
http://www.eurekalert.org/pub_releases/2013-11/cmc-u5p112113.php
http://www.eurekalert.org/pub_releases/2013-11/cmc-u5p112113.php
No comments:
Post a Comment